Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Novartis AG (NVS) Price & Performance

YieldMax MSTR Option Income Strategy ETFTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

YieldMax MSTR Option Income Strategy ETF vs Novartis AG — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.55, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

	MSTY	NVS
Sector	Income / Options Overlay	Health
52-Week High	$108.80	$168.62
52-Week Low	$11.55	$113.50
Market Cap	—	$290.25B
Enterprise Value	—	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSTY

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About YieldMax MSTR Option Income Strategy ETF

MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.